Derivation Web

source_8dc3f795600d45b1

by researka:v2 · 2026-06-24 11:58:22.184436+04:00

# Hypothesis-Generating Brief: Taurine supplementation — full paper

## Abstract

Evidence-honesty note: 46/67 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 59/67 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on Taurine supplementation across 67 accepted source papers and 1827 high-confidence extracted claims.

The evidence profile contains 8 direct clinical sources, 57 adjacent clinical sources, and 2 mechanistic or model-system sources, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes, and negative signals in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Taurine supplementation remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Introduction

Population aging has made the extension of healthspan — the period of life spent in good functional health — a central clinical and public-health priority, and the question of whether any single, scalable intervention can slow the biology of aging itself has become increasingly urgent. These figures help explain why even modest shifts in the rate of functional decline could yield large absolute gains, and why any candidate compound, including taurine, is now being examined against aging-relevant endpoints rather than only against single disease states. The clinical question this synthesis addresses is therefore not whether taurine treats one condition, but whether the evidence base supports a broader claim that taurine influences healthspan or lifespan in humans. Taurine, a sulfur-containing amino acid derivative marketed as a nutritional supplement, has re-entered this conversation largely through preclinical signals rather than through hard-outcome human data.

The geroscience hypothesis holds that targeting the molecular hallmarks of aging may delay multiple chronic conditions simultaneously, and it has reshaped how candidate interventions are evaluated. Rather than requiring a new molecular entity for each disease of late life, the field has become interested in repurposing compounds with favorable safety records and plausible pleiotropic mechanisms. This repositioning raises specific evidentiary demands: investigators now seek evidence that a candidate modulates fundamental aging biology and that any clinical benefit translates into functional or hard-outcome gains in older adults. Taurine fits the repurposing template in principle because it has been studied for decades in cardiometabolic and hepatic indications, and several meta-analyses (e. For example, Waldron 2018; Tzang 2024b) have aggregated trials whose primary endpoints were not aging per se but intermediate phenotypes such as blood pressure. The logic of repurposing is attractive, but it creates a methodological hazard: surrogate endpoints do not guarantee hard-outcome validity (Ioannidis 2005), and findings from disease-specific cohorts may not extrapolate to a generally healthy aging population. Whether taurine clears this bar remains, in our reading, an open question rather than a settled inference.

Several unresolved questions complicate any claim that taurine influences healthspan. First, the translation of mechanistic findings into human functional benefit remains uncertain: rodent and in-vitro signals (e. For example, Elazab 2025; Li 2026; Adamski 2025) coexist with mixed human RCT results, and one recent pilot explicitly framed as testing the taurine-deficiency theory of aging, Marcangeli 2025, has been discussed as offering evidence against that hypothesis in men. Second, apparent tradeoffs exist between outcome domains — for example, Acute Effects of Energy 2025 reports a negative effect on resting blood pressure after energy-drink exposure while Sun 2016 and Waldron 2018 report positive effects on the same outcome after isolated taurine, a tension that has been flagged in the literature and that we treat here as a cross-domain contradiction requiring careful separation rather than simple averaging. Third, population specificity remains unclear: effects in prehypertensive adults (Sun 2016), obese women (Carvalho 2021; Carvalho 2021b), sarcopenic older women (P Physical Exercise 2025), and elderly hip-fracture patients (Stijn 2015) cannot yet be assumed to generalize to a generally healthy aging population. Fourth, the duration required to demonstrate any hard-outcome benefit is unknown; the bulk of trials have follow-up measured in weeks to months.

## Background

Additional corpus sources included animal/preclinical evidence; the background evidence for Taurine supplementation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Sasidharan 2026, Anlacan 2026, Stijn 2015 are interpreted separately from mechanistic studies such as Elazab 2025, Adamski 2025, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes; null signals around the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-taurine-v06-DAILY-2026-06-24T06-06-25Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-24.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `taurine AND aging AND human`
- `taurine supplementation AND randomized trial`
- `taurine AND older adults AND muscle`
- `taurine AND cardiovascular AND meta-analysis`
- `taurine deficiency AND aging`
- `taurine AND lifespan AND mammals`
- `taurine AND blood pressure AND randomized`
- `taurine abundance AND mortality AND cohort`
- `taurine deficiency AND aging AND human cohort`
- `plasma taurine AND older adults AND mortality`
- (... 2 additional queries; see `methods_pack.json` for the full list)

### Eligibility criteria
- Sources whose primary content addresses taurine.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 1261 records in the receipt-candidate union, 1248 were classified as source candidates and 67 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| Receipt candidate union | 1261 |
| Classified source candidates | 1248 |
| No extractable claims | 26 |
| None-only claim binding | 7 |
| Mixed partial-or-none claim-binding candidates | 49 |
| Partial-only claim-binding candidates | 22 |
| Strict high-confidence sources | 16 |
| Admitted final sources | 67 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune and inflammation, longevity, mechanism, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Results
| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Contextual Adjacent Evidence | n=35; claims=1187 | no extracted directional signal in 27/35 sources | 3 direct; 14 indirect; 18 review | limited corpus depth in this outcome class |
| Cardiometabolic | n=13; claims=321 | no extracted directional signal in 6/13 sources | 2 direct; 1 indirect; 10 review | limited corpus depth in this outcome class |
| Immune and Inflammation | n=8; claims=123 | no extracted directional signal in 6/8 sources | 1 direct; 1 indirect; 6 review | limited corpus depth in this outcome class |
| Muscle Function | n=4; claims=52 | no extracted directional signal in 3/4 sources | 1 indirect; 3 review | limited corpus depth in this outcome class |
| Longevity | n=2; claims=9 | unclear signal in 2/2 sources | 1 direct; 1 review | limited corpus depth in this outcome class |
| Mechanism | n=2; claims=45 | no extracted directional signal in 2/2 sources | 2 mechanistic | limited corpus depth in this outcome class |
| Deficiency Prevalence | n=1; claims=13 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Mortality and Survival | n=1; claims=44 | mixed signal in 1/1 sources | 1 direct | single-source slice; hypothesis-generating |
| Safety and Comorbidity | n=1; claims=33 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |















































**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

### Results Summary

- Contextual Adjacent Evidence: n=35; claims=1187; no extracted directional signal in 27/35 sources | directness: 3 direct; 14 indirect; 18 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=13; claims=321; no extracted directional signal in 6/13 sources | directness: 2 direct; 1 indirect; 10 review; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=8; claims=123; no extracted directional signal in 6/8 sources | directness: 1 direct; 1 indirect; 6 review; main limitation: directionally heterogeneous.
- Muscle Function: n=4; claims=52; no extracted directional signal in 3/4 sources | directness: 1 indirect; 3 review; main limitation: no direct clinical anchor.
- Longevity: n=2; claims=9; mixed signal in 2/2 sources | directness: 1 direct; 1 review; main limitation: population and endpoint heterogeneity.
- Mechanism: n=2; claims=45; no extracted directional signal in 2/2 sources | directness: 2 mechanistic; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

The cardiometabolic outcome class dominates the curated corpus, spanning the sources that have been coded to a human or mammalian cardiometabolic endpoint. The bundle ranges from long-term randomized supplementation trials to mechanistic cohort work in animal models, and from prehypertensive adults to frail older women with sarcopenic obesity [Sun 2024; Chu 2026; Sun 2016; Waldron 2018; P Physical Exercise 2025; Guan 2020; Basrai 2019; Acute Effects of Energy 2025; Carvalho 2021; Abud 2022; Tzang 2024b; Verner 2007; Bian 2026]. Translational relevance to humans remains uncertain. The P Physical Exercise 2025 trial focuses on frail older women with sarcopenic obesity under linked protocol NCT05415176, and the Abud 2022 controlled trial enrolls 24 women aged 61.4 ± 4.2 y with BMI 31.4 ± 5.1 kg/m² [P Physical Exercise 2025; Abud 2022]. Together these trials form the empirical backbone for the cardiometabolic direction-of-effect coding reported in the evidence synthesis.

Mechanistically, the cardiometabolic signal in the curated corpus maps onto three overlapping substrates. First, clinical RCT and meta-analytic evidence supports a hemodynamic substrate, in which taurine lowers SBP and DBP and reduces heart rate in prehypertensive and general adult populations [Sun 2016; Waldron 2018; Tzang 2024b]. The mechanistic substrate underlying this functional finding is therefore not unitary: a hemodynamic pathway coexists with an adipose-mitochondrial and a glycemic-lipid pathway, each with its own human RCT, mechanistic, and preclinical anchors. The review tier therefore supplies the class with directional synthesis but inherits the indirectness of its constituent primary studies.

### Deficiency Prevalence Outcomes

One observational cohort contributed direct measurements of circulating taurine concentrations across the adult age span, providing the principal evidence base for the deficiency-prevalence outcome class. The source documents the analytic pipeline but does not report a numeric concentration, prevalence estimate, or age-stratified mean, leaving the quantitative burden of the deficiency claim to be carried by external sources rather than this corpus entry.

Within the curated bundle, Marcangeli 2025 functions as the anchor observational study for the deficiency class and is tagged as indirect in directness with a null effect direction, indicating that the source did not support a clear age-related taurine decrement in this cohort. No p-value, hazard ratio, or prevalence percentage is recorded in the source, which constrains the Results section to qualitative reporting. The lack of an in-source numeric also means that any age-decline claim advanced in the Discussion must be sourced outside the bundle or framed as hypothesis-generating.

Mechanistically, a deficiency-prevalence signal would be expected to surface through reduced systemic taurine availability, plausibly affecting the pathways emphasized elsewhere in the corpus — vascular function, inflammatory tone, and resilience to metabolic stress. The source-traced substrate here is purely a plasma-concentration measurement in a male-only cohort, so the mechanistic link between measured levels and downstream clinical endpoints remains an inference rather than a documented within-source association. Preclinical data in the broader literature are not part of this corpus and are not introduced as numerics.

Within-corpus tensions on the deficiency class are limited because Marcangeli 2025 is the only source mapped to this outcome class, and the cross-study disagreement map records no same-outcome non-orthogonal pairs for deficiency prevalence. The principal limitation is therefore one of coverage rather than disagreement: a single observational cohort cannot adjudicate whether taurine deficiency tracks aging in women, in non-Caucasian populations, or in those with cardiometabolic comorbidity. Cross-study contradictions discussed elsewhere in the paper (for example, between clinical RCTs and mechanistic human studies in cardiometabolic endpoints) do not propagate into this subsection because no second source competes with Marcangeli 2025 on the deficiency question.

### Immune and Inflammation Outcomes

The principal direct interventional hard-endpoint evidence on taurine and inflammation comes from Vahdat 2021, a double-blind randomized controlled trial enrolling adults with traumatic brain injury who received 30 mg/kg/day of taurine in addition to the standard enteral meal. The trial reported a broad battery of inflammatory marker p-values and was coded positive in direction. The study therefore constitutes the single direct, biomarker-anchored RCT in this outcome class within the curated corpus.

Two review-level sources frame the same domain with aggregated controlled-trial data. The juxtaposition of a direct RCT (Vahdat 2021) against two reviews (Faghfouri 2022, Rosa 2014) is the central structural feature of the immune outcome class.

Mechanistically, the positive direct RCT signal in Vahdat 2021 is biologically consistent with taurine's reported actions on oxidative stress and inflammatory cascades, which are the same pathways interrogated in the Faghfouri 2022 pooled analyses. The mechanistic human-study layer (Faghfouri 2022) and the small placebo-controlled biomarker study (Rosa 2014) both engage the redox-inflammation axis, providing a coherent substrate for the clinical RCT's biomarker findings. By contrast, the directness gap between the Vahdat 2021 RCT and the two review-level sources means that the mechanistic substrate is more richly documented than the within-trial clinical translation.

Within-corpus tensions in the immune class are dominated by the directness gap rather than by directional disagreement: Vahdat 2021 is coded positive and direct, whereas Faghfouri 2022 is coded null at the review level and Rosa 2014 contributes indirect review evidence. The bundled cross-study disagreement map explicitly flags indirectness gap (severity 3) for Vahdat 2021 vs Rosa 2014 and for Vahdat 2021 vs Faghfouri 2022, both of which must be interpreted as direct-vs-indirect contrasts rather than as positive-vs-negative contradictions. Readers should therefore treat the apparent direction mismatch in the Findings Map as a directness artifact, not as evidence of biological disagreement, and should refer to the evidence synthesis for the per-study p-value tuples that ground each cell of this subsection.

The immune and inflammation evidence base for taurine comprises five curated sources spanning systematic review, observational cohort, and early-phase clinical designs. Zhao 2025 contributed a comparative nutrition design in yaks, examining rumen-protected taurine for hematological, hepatic, and immune endpoints [Zhao 2025].

Wang 2026 reported a positive directional signal on immune and inflammatory endpoints, with P = 0.03 and P = 0.02 attached to specific marker analyses within the pooled dataset [Wang 2026]. The four remaining sources — Zhao 2025, Chupel 2018, Hove 2019, and Carvalho 2021b — coded null as the directional summary for this outcome class. Chupel 2018 reported at least one P < 0.05 contrast within its multi-arm design [Chupel 2018], and Zhao 2025 surfaced both P > 0.05 and P < 0.05 contrasts across the ruminal, hematological, hepatic, and immune panels it measured [Zhao 2025]. Hove 2019 and Carvalho 2021b provided no extractable p-values in the source bundle. Per the evidence synthesis, which carries every study × p-value tuple for the immune inflammation class, the within-class signal is heterogeneous: a single positive synthesis alongside four null or mixed primary reports.

Mechanistically, the immune-inflammation substrate links taurine to antioxidant defense, cytokine balance, and white adipose tissue remodeling, with both clinical RCT and preclinical data converging on anti-inflammatory plausibility. In a clinical RCT, Carvalho 2021b observed that taurine supplementation in conjunction with exercise modulated cytokines and improved subcutaneous white adipose tissue plasticity in obese women, a finding consistent with the senescence- and inflammation-oriented framing of Wang 2026 [Carvalho 2021b; Wang 2026]. Preclinical and translational data from Hove 2019 extended this anti-inflammatory substrate to a defined metabolic disorder, where taurine treatment was layered onto existing therapy in cystathionine β-synthase deficient homocystinuria and biomarkers of oxidative stress, inflammation, and vascular dysfunction were tracked [Hove 2019]. The mechanistic substrate underlying these immune findings therefore spans adipose-tissue cytokine remodeling, redox balance, and endothelial signaling pathways.

Within-corpus tensions on immune inflammation are partial rather than categorical, and center on the divergence between the positive synthesis of Wang 2026 and the null-coded primary reports of Zhao 2025, Chupel 2018, Hove 2019, and Carvalho 2021b [Wang 2026; Zhao 2025; Chupel 2018; Hove 2019; Carvalho 2021b]. A directness-graded reading of the cross-study disagreement map clarifies the disagreement: Wang 2026 is a systematic review or meta-analysis with a positive directional verdict, whereas Chupel 2018, Hove 2019, and Carvalho 2021b are observational cohort or early-phase clinical designs whose coded directness and effect direction are null, and Zhao 2025 is an indirect observational cohort in a ruminant model. The cross-study contradiction is therefore partly an artifact of design hierarchy and species, and partly a genuine signal conflict that the boundary conditions of dose, population (long-COVID versus elderly, obese, homocystinuric, or ruminant subjects), and concurrent therapy have yet to be resolved.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Longevity Outcomes

Two curated references address longevity-class endpoints for taurine, and they sit at opposite ends of the directness spectrum. Mottaghi 2026, by contrast, is a direct randomized clinical trial among liver transplant recipients examining whether taurine supplementation improves graft function, with mortality reported as a secondary clinical endpoint (Mottaghi 2026). The contrast in design — pooled indirect evidence versus a single direct RCT — frames how each result should be read.

Quantitatively, the two sources diverge. Zhang 2024 reports a non-significant pooled mortality effect (P = 0.45) and a second non-significant endpoint at P = 0.40, with the confidence interval for the mortality estimate crossing unity (Zhang 2024). Mottaghi 2026 reports lower mortality in the taurine arm (P < 0.05), alongside shorter intensive-care-unit stay and shorter total hospital stay, as recorded in the source excerpt (Mottaghi 2026). The numeric contrast between a non-significant pooled RR and a significant within-trial mortality reduction is the central quantitative finding for this outcome class.

Mechanistically, the divergence maps onto differences in population and taurine delivery rather than onto any anti-aging pathway claim. Zhang 2024 evaluates taurine as a feed additive in a heterogeneous critically ill cohort receiving enteral nutrition, where the supplement is a small perturbation on top of standard ICU care (Zhang 2024). Mottaghi 2026 evaluates taurine supplementation in a defined surgical population — liver transplant recipients — where graft recovery and post-operative catabolism plausibly amplify any taurine effect on oxidative and inflammatory load (Mottaghi 2026). The mechanistic substrate underlying the functional finding is therefore population-specific, not a generalized longevity signal.

Within the curated corpus, the longevity-class tension is best characterized as a directness gap rather than a sign disagreement: Mottaghi 2026 reports a positive within-trial effect in a direct RCT, whereas Zhang 2024 reports a non-significant pooled effect in an indirect review (Mottaghi 2026; Zhang 2024). The two sources do not formally contradict on direction — one is significant, the other is null — but they address different populations, different routes of administration, and different control conditions, so their results are not directly comparable. The synthesis brief itself frames this as the boundary condition for any taurine anti-aging claim at present: mechanistic plausibility coexists with mixed or sparse human RCT evidence (PICKED THESIS).

### Mechanism Outcomes

The mechanistic sources in the corpus describe taurine activity in two non-clinical models, both coded as direct mechanistic evidence in adults. Endpoints were molecular (SIRT-1/PGC-1α, NF-κB/iNOS, and p53/Bax/Caspase-3) rather than clinical, and the study therefore informs pathway plausibility rather than human effect size. The source does not report clinical chemistry outcomes as the primary endpoint, and no human RCT is paired with it in the corpus.

No clinical chemistry values, liver enzyme fold-changes, or histology scores are recorded in the supplied excerpt, so any quantitative synthesis is restricted to the molecular layer. The source also does not report effect sizes, confidence intervals, or sample-size justification beyond the per-group n, and these omissions should be carried into the limitations narrative.

Additional corpus sources included animal/preclinical evidence; mechanistically, the Elazab 2025 substrate is consistent with the broader literature framing taurine as a hepatoprotective signaling modulator: the source links antioxidant, anti-inflammatory, and anti-apoptotic readouts within a single experimental design. By contrast, Adamski 2025 operates at a different mechanistic layer, reporting an in-vitro biochemical comparison in which taurine acted as a competitive inhibitor of acetylcholinesterase. The excerpt states that creatine inhibited AChE at 0.0056 ± 0.00018 mM whereas taurine required a higher concentration for comparable inhibition, and the study frames this as a nutritional-modulation hypothesis for brain function. No p-values are reported in the Adamski 2025 excerpt, which constrains any formal significance claim to qualitative effect direction.

Within-corpus tensions in the mechanism class are limited because only two sources share the outcome label, and the cross-study disagreement map records no same-outcome non-orthogonal pairs. The substantive disagreement is therefore not directional but layered: Elazab 2025 implicates hepatic inflammation and apoptosis pathways at 50 mg/kg for 28 days, whereas Adamski 2025 positions taurine as a cholinergic ligand with no in-vivo replication in the corpus. Readers should interpret the two findings as complementary mechanistic substrata rather than competing effect estimates, and any human extrapolation from the 50 mg/kg rat dose should be flagged as a directness gap, since no pharmacokinetic bridging study is included in the bundle.

### Mortality and Survival Outcomes

The only curated trial addressing mortality-class endpoints is Stijn 2015, a randomized clinical trial in elderly hip-fracture patients evaluating perioperative oral taurine supplementation, with a primary biomarker endpoint of postoperative oxidative stress and a morbidity/mortality clinical readout (Stijn 2015). Sample-size and follow-up duration were not available in the available source excerpt for Stijn 2015, so the trial's quantitative footprint is described qualitatively.

The directional summary in the source is coded as 'mixed,' which mirrors the dispersion of p-values — some clearly significant, some marginal, and one non-significant — rather than a uniform benefit or null pattern (Stijn 2015). Because no effect-size point estimates, hazard ratios, or absolute mortality counts are present in the source, no additional quantitative summary is reported here; the evidence synthesis carries the per-comparison p-value tuples.

This is a clinical RCT with a direct, biomarker-anchored endpoint in the target organ system of interest, which raises the mechanistic-to-clinical translation value of any positive signal even when the clinical event counts are sparse.

Within the curated corpus, Stijn 2015 stands alone in the mortality survival outcome class; the cross-study disagreement map contains no same-outcome non-orthogonal pairs, meaning there is no internal contradiction to surface across human trials for this class (Stijn 2015). The principal limitation is therefore not disagreement but sparsity: with one direct clinical RCT and a mixed p-value profile, the mortality-class evidence base for taurine can be interpreted as hypothesis-generating rather than confirmatory, and any aggregate claim of mortality benefit would outrun the sources.

### Muscle Function Outcomes

Four curated studies address taurine and muscle-related endpoints, spanning acute ingestion trials in athletes (Lim 2018, Galan 2018), a longitudinal community-dwelling cohort (Domoto 2024), and a specialty-population chelation adjunct study (Thalassemic Iron Overload 2024). Domoto 2024 followed community-dwelling middle-aged and older Japanese adults over 8 years and tested taurine intake against four physical fitness parameters. Thalassemic Iron Overload 2024 will assess taurine combined with standard chelation therapy at baseline and 12 months via cardiac T2* MRI alongside cardiac function endpoints.

Mechanistically, the acute ergogenic contrasts in Lim 2018 and the training-period contrasts in Galan 2018 are consistent with taurine's proposed roles in excitation-contraction coupling and in attenuating exercise-induced oxidative and inflammatory load, whereas the long-horizon intake association in Domoto 2024 suggests that habitual dietary exposure may align with preservation of fitness components over mid-to-late adulthood. Mechanistic human substrate therefore coexists with longitudinal intake data, but the cross-design translation is partial: Lim 2018 and Galan 2018 capture short-window performance and recovery biology in trained athletes, while Domoto 2024 captures population-level intake associations in community-dwelling adults. The Thalassemic Iron Overload 2024 cardiac-muscle endpoint occupies a distinct mechanistic niche, probing chelation-adjunct effects on iron-overload cardiomyopathy rather than skeletal-muscle performance.

Within-corpus tensions are most visible when the athlete-derived acute and training-window evidence (Lim 2018, Galan 2018) is read against the observational intake-association evidence (Domoto 2024) and the specialty-population cardiac endpoint (Thalassemic Iron Overload 2024). Lim 2018 and Galan 2018 yield significant performance and recovery contrasts in small, controlled athletic samples, whereas Domoto 2024 reports a single P < 0.05 association across four fitness parameters over 8 years without acute mechanistic granularity, and Thalassemic Iron Overload 2024 contributes only a protocol-level endpoint statement with no within-source analytic numerics. The directionality of these four sources is therefore mixed in coding (acute positive in Lim 2018 and Galan 2018; longitudinal positive in Domoto 2024; null at the analytic stage for Thalassemic Iron Overload 2024), and the disagreement is best characterized as a design-population mismatch rather than a contradiction in sign.

### Safety and Comorbidity Outcomes

The single curated source mapped to the safety and comorbidity outcome class, Zinellu 2015, is an observational cohort conducted in adults and presented in review form, with the cited thesis addressing cholesterol-lowering treatment and downstream kynurenine/tryptophan balance in chronic kidney disease (Zinellu 2015). Taurine does not appear in the source's headline outcome, and the source is positioned as background context rather than a primary safety signal. The study reports oxidative-stress-linked serum indices, including malondialdehyde, and the analytic emphasis is on indoleamine 2,3-dioxygenase pathway flux rather than on taurine status. The endpoint structure of the source is therefore a comorbidity-context observation, not a taurine-directed safety test, and any taurine-specific inference must remain indirect.

The source does not supply hazard ratios, mean differences, confidence intervals, or sample sizes tied to taurine exposure, so no taurine-attributable effect size can be reported from this source. Direction of effect is not coded as positive or negative in the curated bundle, and the source's effect direction is recorded as null. This is consistent with its role as a comorbidity-context review rather than as a direct safety endpoint for taurine administration.

Mechanistically, the kynurenine-tryptophan axis represented in Zinellu 2015 is downstream of inflammatory and oxidative-stress signalling, which is the same broad substrate invoked by taurine biology in human mechanistic studies, but the source itself does not measure taurine, taurine conjugates, or related transporters. The relevance to the present synthesis is therefore contextual: it documents a comorbidity (chronic kidney disease) in which redox and inflammatory pathways are dysregulated, and in which taurine biology is plausibly engaged based on external literature, but this engagement is not interrogated within the source. No clinical RCT, mechanistic human study, or preclinical dataset is available within the curated bundle to anchor a taurine-specific safety claim in this outcome class.

Within-corpus tensions in the safety comorbidity class cannot be enumerated, because the curated source bundle includes only one mapped source and the cross-study disagreement map records no same-outcome non-orthogonal pairs. The boundary of the evidence base in this class is therefore a single observational cohort with indirect relevance, and the synthesis cannot adjudicate disagreement where only one source is available. The honest reading is that, for the safety and comorbidity outcome class, the curated evidence for taurine is sparse and indirect, and any narrative that requires stronger safety statements will need additional source-supported sources. Future iterations of the corpus that add direct taurine safety endpoints would be required before the outcome class can support quantitative conclusions.

### Contextual Adjacent Evidence Outcomes

In animal/preclinical evidence, mechanistically, the contextual other corpus covers four plausibly distinct substrates: hepatobiliary, ocular, periodontal/oral mucosal, and renal-erythropoietic. The renal-erythropoietic substrate is mapped by Li 2026, which reports that taurine stimulates EPO production in feline renal cells via the HIF pathway, with cell-viability and downstream marker comparisons significant at P < 0.0001, P < 0.05, P < 0.001, and P < 0.01. These substrates are mechanistically heterogeneous, and the clinical RCT evidence supports each substrate differentially rather than uniformly.

Contextual Adjacent Evidence remains a separate Results slice (n=35; claims=1187; no extracted directional signal in 27/35 sources; 3 direct; 14 indirect; 18 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

## Cross-Domain Synthesis

The single most consequential tension in the taurine literature is the divergence between the largely favorable cardiometabolic literature built on systematic reviews of chronic-dosing trials and the unfavorable acute hemodynamic signal repeatedly generated by energy-drink crossover studies that co-administer caffeine. The disagreement is rated severity 5 in the cross-study disagreement map precisely because three sources on the same outcome class report opposite direction, and a naive reader could pick any one of the three and treat it as definitive. The tension is therefore resolvable rather than a true contradiction, but only if one insists on separating matrix and duration as moderators. Evidence that would resolve it cleanly is a head-to-head randomized acute hemodynamic trial of caffeine, taurine, caffeine+taurine, and double placebo, with SBP/DBP as the primary endpoint; the data required to adjudicate this is not present in the current source set, so the prudent synthesis is that chronic oral taurine shows reproducible cardiometabolic benefit on the order of a few mmHg, while the acute energy-drink literature should not be cited as evidence that taurine itself raises blood pressure.

A second load-bearing tension pits the mechanistic and observational case that taurine deficiency is a driver of human aging against the limited and sometimes null direct evidence that supplementation extends healthy lifespan in older adults. Elazab 2025 demonstrates in rats that taurine attenuates thiamethoxam-induced hepatotoxicity by modulating SIRT-1/PGC-1α and NF-κB pathways at P < 0.01, and Berardi 2025 reports that senescence induction rewires cellular metabolism through a serine/taurine reductive phenotype, both of which are mechanistically consistent with the longevity hypothesis. Marcangeli 2025, by contrast, presents experimental evidence against taurine deficiency as a driver of aging in humans, finding that circulating taurine concentrations are not reduced across the adult age range in men aged 20-100. On the human RCT side, Mottaghi 2026 reports a statistically significant lower mortality signal (P < 0.05) in liver-transplant recipients randomized to taurine, but this is a single small trial in a critically ill population and the effect cannot be generalized to healthy aging. Zhang 2024's meta-analysis of taurine-enhanced enteral nutrition in ICU patients is the most explicit longevity-adjacent test in the bundle, and the pooled mortality result is null (RR = 0.70, P = 0.45, 95% CI [0.28, 1.80], two trials). The boundary condition that emerges is that model-organism and cellular senescence work strongly supports the biological plausibility of taurine as a longevity-relevant molecule, but no human RCT has yet tested the hard endpoint of healthy lifespan extension. The recent surge of protocols (Chu 2026, Bayesian-optimized 3 g/day phase II in healthcare workers; Effects of Daily Taurine 2025, 4 g/day in 55-75-year-olds) suggests this gap is being recognized, but until those trials read out, the longevity claim should be reported as 'mechanistically supported, not clinically demonstrated.' Evidence that would resolve this tension is a long-duration, well-powered RCT with biological-age clocks and hard functional endpoints as co-primaries, run in a population that is not selected for a specific organ-failure indication; the sources do not yet contain such a study.

The underlying mechanism that explains why a positive immune signal might emerge in long-COVID and not in healthy obese or homocystinuria populations is the presence of a chronic inflammatory baseline that taurine can plausibly attenuate through the NLRP3 inflammasome and SIRT-1 pathways; in metabolically healthy or non-inflamed cohorts, there is less signal to detect. Vahdat 2021 reported a dose of 30 mg/kg/day. The boundary condition therefore is that taurine's anti-inflammatory action is most detectable in inflamed or injured populations and is plausibly undetectable above noise in metabolically healthy subjects. The disagreement in the matrix is rated severity 4 because it is a partial conflict rather than a head-on contradiction, and the partial nature is itself informative: the literature is not in dispute about whether taurine has immune effects, only about whether those effects are large enough to detect in any given baseline. Evidence that would resolve the tension is a dose-finding RCT stratified by baseline inflammatory status (low vs high CRP), with the same panel of downstream markers; the current sources do not contain such a stratified design, and Chupel 2018 in elderly women shows only the null side of the contrast.

The mechanistic basis for the athletic signal is taurine's role in excitation-contraction coupling and its antioxidant capacity in working muscle, both of which should in principle translate to older adults. The boundary condition that reconciles the two is acute vs chronic dosing and the relative deficit of baseline taurine status: trained athletes in acute or short-term high-dose protocols (6 g/day or single-dose 2 g pre-exercise) generate measurable performance and recovery gains, while community-dwelling older adults whose habitual taurine intake is captured by food-frequency questionnaires show only weak and inconsistent fitness associations. The synthesis is that the muscle-function literature is internally consistent at the dose-response level (acute high-dose positive in athletes, chronic dietary intake null in elderly) but the clinical-population RCT signals are too few and too small to be sure the effect generalizes.

A fifth and final cross-domain tension is the directness gap between the mechanistic-class evidence (Elazab 2025 on rodent hepatotoxicity, Adamski 2025 on AChE inhibition, Li 2026 on feline renal EPO production) and the human RCT class. Each of the eight direct human RCTs in the source set — Anlacan 2026, Sasidharan 2026, Mottaghi 2022, Mottaghi 2026, Vahdat 2021, Basrai 2019, Stijn 2015, and Chu 2026 (protocol) — uses a different primary endpoint on a different organ system, with the result that no two human RCTs in the bundle can be averaged into a single effect estimate for any unified outcome. The mechanistic literature, by contrast, converges on a small set of pathways (SIRT-1/PGC-1α, NLRP3, NF-κB, AChE, HIF), which makes it tempting to read across the mechanism as if it implied a unified clinical effect. The boundary condition is that the mechanism is shared but the clinical expression is not, because human disease states are not interchangeable with rodent hepatotoxicity models or feline renal cell culture. The synthesis is that the sources collectively support a claim of the form 'taurine modulates several aging- and inflammation-relevant pathways in non-human systems, with corresponding but not equivalent human biomarker and functional signals,' but they do not support a unified clinical claim of the form 'taurine treats aging.' Evidence that would resolve this is a multi-domain human RCT with paired biomarker and hard endpoints; the current source bundle includes one such design in protocol form (Chu 2026) but not in completed form. Until those data arrive, the prudent position is to report mechanistic findings in mechanistic language and clinical findings in clinical language, and to refuse to fuse them into a single causal sentence.## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Taurine produces consistent, modest short-term improvements on surrogate cardiometabolic and contextual endpoints in adults, but the corpus does not yet support durable claims about hard clinical outcomes (mortality, hospitalization, incident frailty) because direct, adequately powered randomized trials with sufficient follow-up remain scarce and the cross-class signals are dominated by reviews rather than primary endpoint trials. Tzang 2024b and Acute Effects of Energy 2025 also register pressure-related effects, although pointing in opposite directions depending on formulation, which we interpret as evidence that the cardiometabolic signal is real but context-dependent on dose, vehicle, and acute-versus-chronic exposure. Within the context-dependent class, we interpret this convergence as the most defensible claim the corpus supports: short-term blood-pressure and lipid-modulation benefits at 1.6–3 g/day appear reproducible, while downstream hard-outcome benefits cannot be defended on current source-level data.

The evidence supports neither reading decisively. We read this threat as qualifying rather than refuting the thesis, because the positive cardiometabolic signal does not depend on the immune class, but it does mean any anti-aging framing that leans on inflammaging reduction is, at present, premature.

Threat 2: The mortality and longevity class is, in our view, the most fragile link in any anti-aging claim. The corpus therefore offers one null ICU signal, one mechanistic-biomarker hip-fracture trial, and one positive transplant trial — too few direct long-term endpoint studies to extrapolate to community-dwelling older adults. Marcangeli 2025 specifically argues against taurine deficiency as a driver of aging in humans, which we interpret as a direct rebuke of the strongest version of the geroprotector thesis. Any longevity recommendation to healthy adults ages 55–75, of the kind the Effects of Daily Taurine 2025 protocol proposes, must therefore be labeled preliminary until hard-endpoint data accrue.

Threat 3: The cross-domain mechanism-versus-clinical gap is the most under-appreciated limitation in the existing literature. The evidence supports a position that mechanistic plausibility is robust but clinically actionable only in narrow windows: prehypertension (Sun 2016), specific surgical populations (Mottaghi 2026, Vahdat 2021), and inflammation-prone deficit states (Wang 2026). Outside those windows, the corpus is consistent with a context-dependent effect that varies by formulation, baseline deficiency, and follow-up window; the generalization to healthy adults remains to be established by adequately powered trials such as Chu 2026.

Population specificity sharpens the clinical-decision boundary. The populations that show null effects include healthy young athletes in heat (Aggett 2025, Peel 2024), community-dwelling adults with usual dietary intake (Marcangeli 2025; Mbilinyi 2025 in COPD), highly trained footballers (Mizera 2026), and post-eccentric-exercise young men (Silva 2014). We interpret this pattern as one in which taurine appears to be useful when a metabolic or inflammatory deficit state is present, and largely inert in replete healthy populations — a "deficit repletion" hypothesis rather than a universal performance or longevity enhancer. The clinical decision boundary, in our view, sits at identifying patients with documented or probable deficiency, target organ stress (transplant, TBI, prehypertension), or sarcopenic obesity, rather than recommending taurine for general healthy aging. First, the mortality question requires a definitive ICU trial to resolve the Zhang 2024 null against the Mottaghi 2026 positive, ideally stratified by baseline taurine status; this is needed because the Zhang 2024 RR = 0.70 (P = 0.45) is consistent with either no effect or a clinically meaningful one, and the trial was underpowered for mortality. Second, a head-to-head trial of isolated taurine versus an energy-drink matrix is required to test whether the Acute Effects of Energy 2025 negative BP signal is vehicle-driven, as we suspect. Third, an adequately powered long-COVID trial with pre-specified inflammatory sub-strata (Wang 2026) is needed to determine whether the positive signal generalizes beyond the long-COVID phenotype or remains limited to it. Fourth, a healthy-adult biological-aging RCT in 55–75-year-olds (Effects of Daily Taurine 2025) using validated aging clocks and ≥24-month follow-up would test the geroprotector hypothesis directly, which Marcangeli 2025 argues is currently unsupported. Until these trials report, the corpus supports a qualified, population-specific recommendation — taurine appears to lower blood pressure in prehypertensive adults (Waldron 2018; Sun 2016), may reduce inflammatory markers in deficit states (Wang 2026), and appears reasonably safe at 1–3 g/day in short-term trials — but cannot, on current evidence, support a general anti-aging or hard-outcome claim in healthy community-dwelling adults.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting
every extracted result into a recommendation. The corpus contains
heterogeneous designs, populations, follow-up windows, and measurement
strategies, so the central question is whether findings travel across
contexts without losing their meaning. Clinical directness, outcome
proximity, consistency of effect direction, and biological plausibility
are therefore weighed together. Where those features align, the
synthesis can support stronger inference; where they diverge, the paper
keeps the conclusion conditional and treats the gap as a research-design
problem for future work.

The interpretation calibrates confidence, clinical meaning, generalizability, and unresolved study-design needs. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

**Resolution criteria:** The thesis would be reinforced by adequately powered trials with pre-specified clinical endpoints, ≥2-year follow-up, intention-to-treat and per-protocol analyses, and concurrent biomarker plus functional measurement. It would be falsified by replicated null findings on those endpoints or by demonstration that any short-term benefit reverses on intervention withdrawal.
## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus contains no long-term, hard-outcome randomized trial in metabolically healthy, non-diabetic community-dwelling adults — the population that most consumer-oriented taurine claims implicitly target. Because no multi-year, low-risk-population RCT sits in the corpus, any inference that taurine supplementation extends healthy lifespan in the general adult population rests on cross-domain extrapolation from short-term biomarker, animal, and high-acuity-patient evidence rather than direct demonstration.

Several outcome domains are represented by a single primary source, which prevents within-corpus replication and leaves each finding vulnerable to a one-study fragility problem. Conclusions anchored to any of these single sources cannot be triangulated against an independent primary trial inside the corpus, so the headline numeric can be interpreted as a one-study estimate rather than a replicated effect.

The enrolled populations are narrow and skewed toward high-acuity, specialty, or animal-model cohorts, so external validity to a healthy adult user is limited. Sex- and age-stratified evidence is thin (e. For example, only one small female-only study is available in the bundle), and no adequately powered trial in pediatric, pregnant, or frail community-dwelling older adults — the population in which the WHO 2000 overweight threshold (25 kg/m²) and the EWGSOP2 sarcopenia cutoffs (Cruz-Jentoft 2019: 27 kg men, 16 kg women) would matter most — is present. Translating any pooled effect to the general, low-risk consumer population is therefore not warranted by the corpus.

Hard clinical endpoints — all-cause mortality, cardiovascular events, incident type 2 diabetes, fragility fractures, and validated cognitive decline — are largely unmeasured or measured only as surrogate biomarkers in this evidence base.

Several clinically popular claims rest almost entirely on mechanistic or animal-model evidence, with no adequate human-RCT counterpart in the corpus. The longevity / anti-aging thesis is supported preclinically by El 2025 (60% stroke-volume rise and doubled cardiac output in heat-stressed brook char), Shao 2025 (sleep-deprived mouse skin barrier), Adamski 2025 (in-vitro AChE inhibition), Elazab 2025 (rat hepatotoxicity at 50 mg/kg, P < 0.01), and Li 2026 (feline renal-cell EPO induction via HIF, P < 0.0001), but the only directly coded human longevity/sarcopenia primary study is P Physical Exercise 2025 (NCT05415176, older women with sarcopenic obesity, P = 0.007–0.038 across metabolic markers). Mechanistic and animal data (Elazab 2025; Li 2026; Adamski 2025; Berardi 2025) and observational deficiency cohorts (Marcangeli 2025) reinforce biological plausibility without delivering hard-outcome human evidence. The practice boundary this synthesis supports is therefore narrow: taurine may be considered off-label and only within supervised trials or for narrowly defined cardiometabolic adjunct indications, and pending further trials it should not be marketed or prescribed as a standalone anti-aging therapy.

## What This Synthesis Adds

This synthesis maps 67 included sources on Taurine across 10 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 67 curated reference papers, the evidence base for taurine shows a context-dependent profile. Positive signals appear in: contextual other, cardiometabolic. Negative signals appear in: cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The taurine anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the disagreement between Acute Effects of Energy 2025 and Sun 2016 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Sun 2024, Tzang 2024, Wang 2026, Waldron 2018, Almohaimeed 2024) emphasize convergent signals on Taurine. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| muscle function | 0 | 4 | null, unclear | direct interventional hard-endpoint gap |
| mechanism | 0 | 2 | null | direct interventional hard-endpoint gap |
| longevity | 1 | 1 | unclear | replication gap |
| cardiometabolic | 2 | 11 | mixed, negative, null, positive | conflict-resolution gap |
| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 1 | 2 | null, positive | replication gap |
| immune and inflammation | 0 | 5 | null, positive | conflict-resolution gap |
| safety and comorbidity | 0 | 1 | null | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 3 | 32 | null, positive | conflict-resolution gap |
| mortality and survival | 1 | 0 | mixed | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | muscle function: direct interventional hard-endpoint gap | 0 direct and 4 indirect sources; direction profile: null, unclear |
| P2 | mechanism: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |
| P3 | longevity: replication gap | 1 direct and 1 indirect sources; direction profile: unclear |
| P4 | cardiometabolic: conflict-resolution gap | 2 direct and 11 indirect sources; direction profile: mixed, negative, null, positive |
| P5 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Taurine should target the **muscle function** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Tensions and Gaps

Evidence-gap priority: The tension analysis separates claim-level disagreement counts from substantive cross-context evidence gaps. Biomarker-positive source-level findings are not pooled with mixed or null clinical-endpoint findings. The unresolved breadth therefore spans the reviewer-named adjacent contexts, and these contexts remain hypothesis-generating unless represented by retained direct clinical endpoint evidence. The manuscript reports 727 claim-level cross-study disagreements from the manifest; that number is a claim-level count, not an independently pooled source-pair count. Actually surfaced tensions include:
- Chu 2026 vs Basrai 2019: surfaced tension/disagreement in Cardiometabolic because directions are positive versus negative.
- Anlacan 2026 vs Bilgin 2026: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are null versus positive.
- Vahdat 2021 vs Faghfouri 2022: surfaced tension/disagreement in Immune and Inflammation because directions are positive versus null.

## Evidence Snapshot

Topic-fit rationale: Sources are retained only when they operationalize taurine directly or provide adjacent/contextual boundary evidence for the same construct. 8/67 retained sources are classified as direct; adjacent, contextual, review-level, or mechanistic sources are reclassified as boundary evidence rather than used for broad efficacy claims. Representative source-fit checks: Yanni 2025 (indirect; Contextual Adjacent Evidence), Sun 2024 (review; Cardiometabolic), Tzang 2024 (review; Contextual Adjacent Evidence), Sasidharan 2026 (direct; Contextual Adjacent Evidence), Peel 2024 (indirect; Contextual Adjacent Evidence).

Source directness breakdown: 8/67 retained sources directly address the stated topic and aging-relevant hard endpoints; 59/67 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims.

### Source Outcome-Class Map

Tension-accounting note: disagreement counts are claim-level. Substantive tension still remains between biomarker-elevating studies and mixed/null clinical-endpoint studies, so these contrasts are treated as unresolved evidence gaps.

- Yanni 2025: Amino acid composition of plant protein-enriched wheat biscuits differentially affects postprandial amino acid responses of overweight/obese compared to normalweight subjects: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Sun 2024: Effect of Long-Term Taurine Supplementation on the Lipid and Glycaemic Profile in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.

- Tzang 2024: Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1.

- Sasidharan 2026: A randomized controlled trial of L -taurine for fatigue in decompensated cirrhosis: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1.

- Peel 2024: The effect of 8-day oral taurine supplementation on thermoregulation during low-intensity exercise at fixed heat production in hot conditions of incremental humidity: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Anlacan 2026: A nutritional blend of taurine, vitamins B6, B9, and B12 improves motivated behaviors in healthy adults—a double-blinded randomized clinical trial: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1.

- Bilgin 2026: Post-activation performance enhancement (PAPE) and taurine combination improves anaerobic performance in highly trained wrestlers: a double-blind, randomized, crossover study: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2.

- In animal/preclinical evidence, Li 2026: Taurine stimulates EPO production in feline renal cells through the HIF pathway: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Stijn 2015: Effect of Oral Taurine on Morbidity and Mortality in Elderly Hip Fracture Patients: A Randomized Trial: outcome=Mortality and Survival; direction=mixed; directness=direct; tier=A1.

- Elazab 2025: Gallic Acid and Taurine Attenuate Thiamethoxam-Induced Hepatotoxicity in Rats by Modulating SIRT-1/PGC-1α, NF-κB/iNOS, and p53/Bax/Caspase-3 Pathways: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1.

- Aggett 2025: Acute Effects of Caffeine and Taurine Co‐Ingestion on Time to Exhaustion and Thermoregulatory Responses to Cycling in the Heat: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Sayedyousef 2025: Taurine, Sirtuin-1 and TNF- α levels in different aged adults with periodontitis: a pilot study: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2.

- Mizera 2026: Effects of Taurine-, Caffeine-, and Phosphatidylserine-Containing Supplementation Protocols on Physical and Cognitive Performance in Professional Male Football Players: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Wang 2026: Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis: outcome=Immune and Inflammation; direction=positive; directness=review; tier=B1.

- Vahdat 2021: The effects of Taurine supplementation on inflammatory markers and clinical outcomes in patients with traumatic brain injury: a double-blind randomized controlled trial: outcome=Immune and Inflammation; direction=positive; directness=direct; tier=A1.

- Chu 2026: Effects of taurine supplementation on metabolic health and biological aging in healthcare workers: A protocol for a triple-blinded, Bayesian-optimized phase II randomized controlled trial: outcome=Cardiometabolic; direction=positive; directness=direct; tier=A1.

- Zinellu 2015: Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2.

- Bian 2026: Effect of Dietary Taurine on the Innate Immune Responses, Digestive Function, and mTOR Signaling in Coho Salmon ( Oncorhynchus kisutch ): outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2.

- Domoto 2024: Association of taurine intake with changes in physical fitness among community-dwelling middle-aged and older Japanese adults: an 8-year longitudinal study: outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2.

- Tzang 2024b: Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2.

- Huo 2026: Maternal dietary taurine supplementation improves intestinal health of lambs via modulating gut microbiota and barrier function: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2.

- Hamada 2011: Possible Association of High Urinary Magnesium and Taurine to Creatinine Ratios with Metabolic Syndrome Risk Reduction in Australian Aboriginals: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Deng 2025: Caffeine and taurine: a systematic review and network meta-analysis of their individual and combined effects on physical capacity, cognitive function, and physiological markers: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- Zhao 2025: Effects of Rumen-Protected Taurine Supplementation on Ruminal Fermentation, Hematological Profiles, Liver Function, and Immune Responses in Yaks: outcome=Immune and Inflammation; direction=null; directness=indirect; tier=B2.

- Berardi 2025: Senescence Cell Induction Methods Display Diverse Metabolic Reprogramming and Reveal an Underpinning Serine/Taurine Reductive Metabolic Phenotype: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Lim 2018: The Effect of Acute Taurine Ingestion on Human Maximal Voluntary Muscle Contraction.: outcome=Muscle Function; direction=null; directness=review; tier=B2.

- Guan 2020: The effects of taurine supplementation on obesity, blood pressure and lipid profile: A meta-analysis of randomized controlled trials.: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.

- P Physical Exercise 2025: 1751-P: Physical Exercise Associated or Not with Taurine Supplementation—Impacts on Metabolic Health in Older Women with Sarcopenic Obesity: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.

- Marcangeli 2025: Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans: outcome=Deficiency Prevalence; direction=null; directness=indirect; tier=B2.

- Faghfouri 2022: Profiling inflammatory and oxidative stress biomarkers following taurine supplementation: a systematic review and dose-response meta-analysis of controlled trials.: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.

- Sinha 2024: Systematic Review and Meta‐Analysis: Taurine and Its Association With Colorectal Carcinoma: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- Arrieta 2014: Phase IV prospective clinical study to evaluate the effect of taurine on liver function in postsurgical adult patients requiring parenteral nutrition.: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Chupel 2018: Exercise and taurine in inflammation, cognition, and peripheral markers of blood-brain barrier integrity in older women.: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.

- Waldron 2018: The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis.: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1.

- Basrai 2019: Energy Drinks Induce Acute Cardiovascular and Metabolic Changes Pointing to Potential Risks for Young Adults: A Randomized Controlled Trial.: outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1.

- Mbilinyi 2025: Prolonged increase in glutamate whole body and intracellular production in older adults with COPD and healthy controls post-resistance exercise.: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- Almohaimeed 2024: Investigating the potential neuroprotective benefits of taurine and Dihydrotestosterone and Hydroxyprogesterone levels in SH-SY5Y cells: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1.

- Silva 2014: Effects of taurine supplementation following eccentric exercise in young adults.: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- Acute Effects of Energy 2025: The acute effects of energy drink with taurine on resting blood pressure in healthy young adults: A systematic review with meta-analysis: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1.

- Rosa 2014: Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study.: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.

### Load-Bearing Included Studies

- Sasidharan 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.05.
- Anlacan 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.056.
- Stijn 2015; tier=A1; directness=direct; endpoint=mortality survival; direction=mixed; representative statistic=P = 0.00.
- Vahdat 2021; tier=A1; directness=direct; endpoint=immune; direction=positive; representative statistic=P = 0.003.
- Chu 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.001.
- Basrai 2019; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
- Mottaghi 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Mottaghi 2026; tier=A1; directness=direct; endpoint=longevity; direction=unclear; representative statistic=P < 0.05.
- Sun 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.00001.
- Tzang 2024; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 5 disagreement: Acute Effects of Energy 2025 vs Sun 2016; Acute Effects of Energy 2025 reports negative effect on cardiometabolic; Sun 2016 reports positive on the same outcome — direct conflict
- Severity 5 disagreement: Acute Effects of Energy 2025 vs Waldron 2018; Acute Effects of Energy 2025 reports negative effect on cardiometabolic; Waldron 2018 reports positive on the same outcome — direct conflict
- Severity 5 disagreement: Tzang 2024b vs Sun 2016; Tzang 2024b reports negative effect on cardiometabolic; Sun 2016 reports positive on the same outcome — direct conflict
- Severity 5 disagreement: Tzang 2024b vs Waldron 2018; Tzang 2024b reports negative effect on cardiometabolic; Waldron 2018 reports positive on the same outcome — direct conflict
- Severity 5 disagreement: Chu 2026 vs Basrai 2019; Chu 2026 reports positive effect on cardiometabolic; Basrai 2019 reports negative on the same outcome — direct conflict
- Severity 4 null vs negative: P Physical Exercise 2025 vs Acute Effects of Energy 2025; Acute Effects of Energy 2025 (negative on cardiometabolic) vs P Physical Exercise 2025 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: P Physical Exercise 2025 vs Tzang 2024b; Tzang 2024b (negative on cardiometabolic) vs P Physical Exercise 2025 (null on cardiometabolic) — partial conflict
- Severity 4 null vs negative: Acute Effects of Energy 2025 vs Bian 2026; Acute Effects of Energy 2025 (negative on cardiometabolic) vs Bian 2026 (null on cardiometabolic) — partial conflict

## Conclusion

For Taurine supplementation, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.

Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Tang 2021, Gultekin 2012, Yu 2024, Duan 2023, Gao 2019, Bae 2019, Funke 2012, Gavriel 2025, Guan 2025, Kim 2026, Samadi 2021.

## References

- **Yanni 2025.** _Amino acid composition of plant protein-enriched wheat biscuits differentially affects postprandial amino acid responses of overweight/obese compared to normalweight subjects._ European Journal of Nutrition, 2025. DOI: 10.1007/s00394-025-03759-x. PMID: 40690028.
- **Sun 2024.** _Effect of Long-Term Taurine Supplementation on the Lipid and Glycaemic Profile in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis._ Nutrients, 2024. DOI: 10.3390/nu17010055. PMID: 39796489.
- **Tzang 2024.** _Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials._ Nutrition & Diabetes, 2024. DOI: 10.1038/s41387-024-00289-z. PMID: 38755142.
- **Sasidharan 2026.** _A randomized controlled trial of L -taurine for fatigue in decompensated cirrhosis._ Hepatology Communications, 2026. DOI: 10.1097/HC9.0000000000000938. PMID: 42043864.
- **Peel 2024.** _The effect of 8-day oral taurine supplementation on thermoregulation during low-intensity exercise at fixed heat production in hot conditions of incremental humidity._ European Journal of Applied Physiology, 2024. DOI: 10.1007/s00421-024-05478-3. PMID: 38582816.
- **Anlacan 2026.** _A nutritional blend of taurine, vitamins B6, B9, and B12 improves motivated behaviors in healthy adults—a double-blinded randomized clinical trial._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1711478. PMID: 41889717.
- **Bilgin 2026.** _Post-activation performance enhancement (PAPE) and taurine combination improves anaerobic performance in highly trained wrestlers: a double-blind, randomized, crossover study._ Journal of the International Society of Sports Nutrition, 2026. DOI: 10.1080/15502783.2026.2673071. PMID: 42112616.
- **Li 2026.** _Taurine stimulates EPO production in feline renal cells through the HIF pathway._ Scientific Reports, 2026. DOI: 10.1038/s41598-026-46877-0. PMID: 41957466.
- **Stijn 2015.** _Effect of Oral Taurine on Morbidity and Mortality in Elderly Hip Fracture Patients: A Randomized Trial._ International Journal of Molecular Sciences, 2015. DOI: 10.3390/ijms160612288. PMID: 26035756.
- **Elazab 2025.** _Gallic Acid and Taurine Attenuate Thiamethoxam-Induced Hepatotoxicity in Rats by Modulating SIRT-1/PGC-1α, NF-κB/iNOS, and p53/Bax/Caspase-3 Pathways._ Pharmaceuticals, 2025. DOI: 10.3390/ph18081112. PMID: 40872506.
- **Aggett 2025.** _Acute Effects of Caffeine and Taurine Co‐Ingestion on Time to Exhaustion and Thermoregulatory Responses to Cycling in the Heat._ European Journal of Sport Science, 2025. DOI: 10.1002/ejsc.70044. PMID: 40956767.
- **Sayedyousef 2025.** _Taurine, Sirtuin-1 and TNF-α levels in different aged adults with periodontitis: a pilot study._ BMC Oral Health, 2025. DOI: 10.1186/s12903-025-06690-z. PMID: 40847336.
- **Mizera 2026.** _Effects of Taurine-, Caffeine-, and Phosphatidylserine-Containing Supplementation Protocols on Physical and Cognitive Performance in Professional Male Football Players._ Nutrients, 2026. DOI: 10.3390/nu18111684. PMID: 42280328.
- **Wang 2026.** _Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis._ BMC Infectious Diseases, 2026. DOI: 10.1186/s12879-026-13009-y. PMID: 41803812.
- **Vahdat 2021.** _The effects of Taurine supplementation on inflammatory markers and clinical outcomes in patients with traumatic brain injury: a double-blind randomized controlled trial._ Nutrition Journal, 2021. DOI: 10.1186/s12937-021-00712-6. PMID: 34103066.
- **Chu 2026.** _Effects of taurine supplementation on metabolic health and biological aging in healthcare workers: A protocol for a triple-blinded, Bayesian-optimized phase II randomized controlled trial._ PLOS One, 2026. DOI: 10.1371/journal.pone.0350389. PMID: 42201902.
- **Zinellu 2015.** _Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement._ Nutr Metab Cardiovasc Dis, 2015. DOI: 10.1016/j.numecd.2014.11.004. PMID: 25534866.
- **Bian 2026.** _Effect of Dietary Taurine on the Innate Immune Responses, Digestive Function, and mTOR Signaling in Coho Salmon ( Oncorhynchus kisutch )._ Aquaculture Nutrition, 2026. DOI: 10.1155/anu/7769837. PMID: 41783608.
- **Domoto 2024.** _Association of taurine intake with changes in physical fitness among community-dwelling middle-aged and older Japanese adults: an 8-year longitudinal study._ Frontiers in Nutrition, 2024. DOI: 10.3389/fnut.2024.1337738. PMID: 38571751.
- **Tzang 2024b.** _Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis._ Nutrition Journal, 2024. DOI: 10.1186/s12937-024-00995-5. PMID: 39148075.
- **Huo 2026.** _Maternal dietary taurine supplementation improves intestinal health of lambs via modulating gut microbiota and barrier function._ Frontiers in Microbiology, 2026. DOI: 10.3389/fmicb.2026.1662296. PMID: 41777538.
- **Hamada 2011.** _Possible Association of High Urinary Magnesium and Taurine to Creatinine Ratios with Metabolic Syndrome Risk Reduction in Australian Aboriginals._ Cardiology Research and Practice, 2011. DOI: 10.4061/2011/235653. PMID: 21738855.
- **Deng 2025.** _Caffeine and taurine: a systematic review and network meta-analysis of their individual and combined effects on physical capacity, cognitive function, and physiological markers._ Journal of the International Society of Sports Nutrition, 2025. DOI: 10.1080/15502783.2025.2566371. PMID: 41032459.
- **Zhao 2025.** _Effects of Rumen-Protected Taurine Supplementation on Ruminal Fermentation, Hematological Profiles, Liver Function, and Immune Responses in Yaks._ Animals : an Open Access Journal from MDPI, 2025. DOI: 10.3390/ani15131929. PMID: 40646828.
- **Berardi 2025.** _Senescence Cell Induction Methods Display Diverse Metabolic Reprogramming and Reveal an Underpinning Serine/Taurine Reductive Metabolic Phenotype._ Aging Cell, 2025. DOI: 10.1111/acel.70127. PMID: 40530891.
- **Lim 2018.** _The Effect of Acute Taurine Ingestion on Human Maximal Voluntary Muscle Contraction._ Med Sci Sports Exerc, 2018. DOI: 10.1249/mss.0000000000001432. PMID: 28945675.
- **Guan 2020.** _The effects of taurine supplementation on obesity, blood pressure and lipid profile: A meta-analysis of randomized controlled trials._ Eur J Pharmacol, 2020. DOI: 10.1016/j.ejphar.2020.173533. PMID: 32871172.
- **P Physical Exercise 2025.** _1751-P: Physical Exercise Associated or Not with Taurine Supplementation—Impacts on Metabolic Health in Older Women with Sarcopenic Obesity._ Diabetes, 2025. DOI: 10.2337/db25-1751-p.
- **Marcangeli 2025.** _Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans._ Aging Cell, 2025. DOI: 10.1111/acel.70191. PMID: 41061678.
- **Faghfouri 2022.** _Profiling inflammatory and oxidative stress biomarkers following taurine supplementation: a systematic review and dose-response meta-analysis of controlled trials._ Eur J Clin Nutr, 2022. DOI: 10.1038/s41430-021-01010-4. PMID: 34584225.
- **Sinha 2024.** _Systematic Review and Meta‐Analysis: Taurine and Its Association With Colorectal Carcinoma._ Cancer Medicine, 2024. DOI: 10.1002/cam4.70424. PMID: 39632512.
- **Arrieta 2014.** _Phase IV prospective clinical study to evaluate the effect of taurine on liver function in postsurgical adult patients requiring parenteral nutrition._ Nutr Clin Pract, 2014. DOI: 10.1177/0884533614533610. PMID: 24829298.
- **Chupel 2018.** _Exercise and taurine in inflammation, cognition, and peripheral markers of blood-brain barrier integrity in older women._ Appl Physiol Nutr Metab, 2018. DOI: 10.1139/apnm-2017-0775. PMID: 29474803.
- **Waldron 2018.** _The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis._ Curr Hypertens Rep, 2018. DOI: 10.1007/s11906-018-0881-z. PMID: 30006901.
- **Basrai 2019.** _Energy Drinks Induce Acute Cardiovascular and Metabolic Changes Pointing to Potential Risks for Young Adults: A Randomized Controlled Trial._ J Nutr, 2019. DOI: 10.1093/jn/nxy303. PMID: 30805607.
- **Mbilinyi 2025.** _Prolonged increase in glutamate whole body and intracellular production in older adults with COPD and healthy controls post-resistance exercise._ Metabolism, 2025. DOI: 10.1016/j.metabol.2025.156185. PMID: 40113079.
- **Almohaimeed 2024.** _Investigating the potential neuroprotective benefits of taurine and Dihydrotestosterone and Hydroxyprogesterone levels in SH-SY5Y cells._ Front Aging Neurosci, 2024. DOI: 10.3389/fnagi.2024.1379431. PMID: 38867846.
- **Silva 2014.** _Effects of taurine supplementation following eccentric exercise in young adults._ Appl Physiol Nutr Metab, 2014. DOI: 10.1139/apnm-2012-0229. PMID: 24383513.
- **Acute Effects of Energy 2025.** _The acute effects of energy drink with taurine on resting blood pressure in healthy young adults: A systematic review with meta-analysis._ Clinics Biopsychosocial, 2025. DOI: 10.54727/cbps.v2.i1.33.
- **Rosa 2014.** _Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study._ Eur J Nutr, 2014. DOI: 10.1007/s00394-013-0586-7. PMID: 24065043.
- **Tang 2021.** _Bigu-Style Fasting Affects Metabolic Health by Modulating Taurine, Glucose, and Cholesterol Homeostasis in Healthy Young Adults._ J Nutr, 2021. DOI: 10.1093/jn/nxab123. PMID: 33979839.
- **Gultekin 2012.** _Effect of the topical use of the antioxidant taurine on the two basement membrane proteins of regenerating oral gingival epithelium._ J Periodontol, 2012. DOI: 10.1902/jop.2011.100568. PMID: 21574832.
- **Carvalho 2021.** _Taurine supplementation associated with exercise increases mitochondrial activity and fatty acid oxidation gene expression in the subcutaneous white adipose tissue of obese women._ Clin Nutr, 2021. DOI: 10.1016/j.clnu.2020.09.044. PMID: 33051044.
- **Mottaghi 2022.** _The effect of taurine supplementation on delirium post liver transplantation: A randomized controlled trial._ Clin Nutr, 2022. DOI: 10.1016/j.clnu.2022.07.042. PMID: 36081295.
- **Yu 2024.** _Effects of Caffeine-Taurine Co-Ingestion on Endurance Cycling Performance in High Temperature and Humidity Environments._ Sports Health, 2024. DOI: 10.1177/19417381241231627. PMID: 38406865.
- **Duan 2023.** _Taurine: A Source and Application for the Relief of Visual Fatigue._ Nutrients, 2023. DOI: 10.3390/nu15081843. PMID: 37111062.
- **Shao 2025.** _Taurine Prevents Impairments in Skin Barrier Function and Dermal Collagen Synthesis Triggered by Sleep Deprivation-Induced Estrogen Circadian Rhythm Disruption._ Cells, 2025. DOI: 10.3390/cells14100727. PMID: 40422230.
- **Verner 2007.** _Effect of taurine supplementation on growth and development in preterm or low birth weight infants._ Cochrane Database Syst Rev, 2007. DOI: 10.1002/14651858.cd006072.pub2. PMID: 17943882.
- **Sun 2016.** _Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study._ Hypertension, 2016. DOI: 10.1161/hypertensionaha.115.06624. PMID: 26781281.
- **Gao 2019.** _Effects of Dietary Taurine Supplementation on Blood and Urine Taurine Concentrations in the Elderly Women with Dementia._ Adv Exp Med Biol, 2019. DOI: 10.1007/978-981-13-8023-5_22. PMID: 31468402.
- **Bae 2019.** _The Development of Taurine Supplementary Menus for the Prevention of Dementia and Their Positive Effect on the Cognitive Function in the Elderly with Dementia._ Adv Exp Med Biol, 2019. DOI: 10.1007/978-981-13-8023-5_32. PMID: 31468412.
- **Abud 2022.** _Taurine as a possible antiaging therapy: A controlled clinical trial on taurine antioxidant activity in women ages 55 to 70._ Nutrition, 2022. DOI: 10.1016/j.nut.2022.111706. PMID: 35700594.
- **Zhang 2024.** _Efficacy of taurine-enhanced enteral nutrition in improving the outcomes of critically ill patients: A systematic review and meta-analysis._ Clin Nutr ESPEN, 2024. DOI: 10.1016/j.clnesp.2024.03.012. PMID: 38777434.
- **Effects of Daily Taurine 2025.** _Effects Of Daily Taurine Intake For 6 Months On Biological Age and Body Metabolism Indicators As Well As Physical Fitness In 55-75-year-old Women And Men._ 2025. Identifier unavailable; no DOI or PMID in source metadata.
- **Galan 2018.** _Effects of taurine on markers of muscle damage, inflammatory response and physical performance in triathletes._ J Sports Med Phys Fitness, 2018. DOI: 10.23736/s0022-4707.17.07497-7. PMID: 28745470.
- **Hove 2019.** _Biomarkers of oxidative stress, inflammation, and vascular dysfunction in inherited cystathionine β-synthase deficient homocystinuria and the impact of taurine treatment in a phase 1/2 human clinical trial._ J Inherit Metab Dis, 2019. DOI: 10.1002/jimd.12085. PMID: 30873612.
- **Mottaghi 2026.** _Could taurine supplementation improve graft functions after liver transplantation? A randomized clinical trial among liver transplant recipients._ Clin Nutr ESPEN, 2026. DOI: 10.1016/j.clnesp.2026.102920. PMID: 41605371.
- **Adamski 2025.** _Creatine and Taurine as Novel Competitive Inhibitors of Acetylcholinesterase: A Biochemical Basis for Nutritional Modulation of Brain Function._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms262311309. PMID: 41373466.
- **Carvalho 2021b.** _Taurine supplementation in conjunction with exercise modulated cytokines and improved subcutaneous white adipose tissue plasticity in obese women._ Amino Acids, 2021. DOI: 10.1007/s00726-021-03041-4. PMID: 34255136.
- **El 2025.** _Taurine efflux counters the hydrodynamic impact of anaerobic metabolism to protect cardiorespiratory function under acute thermal stress in brook char (Salvelinus fontinalis)._ J Exp Biol, 2025. DOI: 10.1242/jeb.249418. PMID: 39670535.
- **Funke 2012.** _Longitudinal analysis of taurine induced effects on the tear proteome of contact lens wearers and dry eye patients using a RP-RP-Capillary-HPLC-MALDI TOF/TOF MS approach._ J Proteomics, 2012. DOI: 10.1016/j.jprot.2012.03.018. PMID: 22480906.
- **Gavriel 2025.** _Reduced taurine transporter expression in lymphoblastoid cell lines from Alzheimer’s disease patients compared with age-matched controls: Therapeutic implications?._ bioRxiv preprint, 2025. DOI: 10.1101/2025.03.31.646363.
- **Guan 2025.** _Hormetic elevation of taurine restrains inflammaging by deactivating the NLRP3 inflammasome._ bioRxiv preprint, 2025. DOI: 10.1101/2025.05.27.656381.
- **Does Taurine Supplementation n.d..** _Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?._ 2027. Identifier unavailable; no DOI or PMID in source metadata.
- **Thalassemic Iron Overload 2024.** _Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine Supplementation._ 2024. Identifier unavailable; no DOI or PMID in source metadata.
- **Kim 2026.** _Transcriptomic profiling of chlorogenic acid and taurine treatment in human skin cells provides insights into cellular senescence mechanisms._ Frontiers in Molecular Biosciences, 2026. DOI: 10.3389/fmolb.2026.1748185. PMID: 41938013.
- **Samadi 2021.** _The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study._ Life Sci, 2021. DOI: 10.1016/j.lfs.2020.118813. PMID: 33275984.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.
- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.
- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "d67c8bc4-a970-4f83-bfdc-b241d417b787",
  "title": "Hypothesis-Generating Brief: Taurine supplementation \u2014 full paper"
}